ArticleMaterials (Basel, Switzerland)2011
Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials.
Article in Materials (Basel, Switzerland), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Teriparatide as a non-surgical salvage therapy for prolonged humerus fracture nonunion: A case report and literature review.World journal of orthopedics · 2025Article
- Parathyroid hormone (1-34) promotes the effects of 3D printed scaffold-seeded bone marrow mesenchymal stem cells on meniscus regeneration.Stem cell research & therapy · 2020Article
- Article
- Obesity/type 2 diabetes increases inflammation, periosteal reactive bone formation, and osteolysis during Staphylococcus aureus implant-associated bone infection.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2018Article
- Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects on New Bone Formation and Non-Anabolic Effects on Inhibition of Mast Cells in a Murine Cranial Window Model.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Article
- Article
- Local pulsatile PTH delivery regenerates bone defects via enhanced bone remodeling in a cell-free scaffold.Biomaterials · 2017Article
- Animal models of osteogenesis imperfecta: applications in clinical research.Orthopedic research and reviews · 2016Review
- Delayed fracture healing and increased callus adiposity in a C57BL/6J murine model of obesity-associated type 2 diabetes mellitus.PloS one · 2014Article
- Advances in regenerative orthopedics.Mayo Clinic proceedings · 2013Article
- Teriparatide: a novel means to ultimately achieve true regeneration!!!Journal of clinical and diagnostic research : JCDR · 2013Article
- Emerging ideas: Engineering the periosteum: revitalizing allografts by mimicking autograft healing.Clinical orthopaedics and related research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Critically sized large bone defects commonly result from trauma, radical tumor resections or infections. Currently, massive allografting remain as the clinical standard to treat these critical defects. Unfortunately, allograft healing is limited by the lack of osteogenesis and bio-integration of the graft to the host bone. Based on its widely studied anabolic effects on the bone, we have proposed that teriparatide [recombinant parathyroid hormone (PTH(1-34))] could be an effective adjuvant for massive allograft healing. In support of this theory, here we review studies that have demonstrated that intermittent PTH(1-34) treatment enhances and accelerates the skeletal repair process via a number of mechanisms including: effects on mesenchymal stem cells (MSC), angiogenesis, chondrogenesis, bone formation and remodeling. We also review the current literature on the effects of PTH(1-34) therapy on bone healing, and discuss this drug's long term potential as an adjuvant for endogenous tissue engineering.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.